Treatment of advanced Parkinson's disease with dopamine agonists
作者： Abraham N. Lieberman , Menek Goldstein
DOI: 10.1016/B978-0-407-02295-9.50014-X
关键词:
摘要: Publisher Summary This chapter discusses the treatment of advanced Parkinson's disease with dopamine agonists. The response to levodopa in patients diminishes considerably after a few years treatment. Associated diminished are on–off phenomena, and associated phenomena dyskinesias. Given complexities underlying most successful means treating both these states has been through augmenting activity dopaminergic system drugs that bypass degenerating presynaptic nigrostriatal neurons stimulate postsynaptic receptors directly. Apomorphine was first agonist be used man. availability preferentially activate one or another class opens up several new therapeutic strategies.
sci-hub.st 参考文章(75)
Paul F. Teychenne, E. Anthony Jones, Kamal G. Ishak, Donald B. Calne, Hepatocellular Injury with Distinctive Mitochondrial Changes Induced by Lergotrile Mesylate: A Dopaminetgic Ergot Derivative Gastroenterology. ,vol. 76, pp. 575- 583 ,(1979) , 10.1016/S0016-5085(79)80227-9
Erik Birket-Smith, Jette BØttcher, Erik Dupont, Per Holm, John P. A. Jensen, Ole Kristensen, Ole KØhler, Bent Mikkelsen, Dopaminergic agonist Ro 8–4650 in Parkinson's disease Acta Neurologica Scandinavica. ,vol. 58, pp. 74- 76 ,(1978) , 10.1111/J.1600-0404.1978.TB02862.X
T. N. Chase, A. C. Woods, G. A. Glaubiger, Parkinson Disease Treated With a Suspected Dopamine Receptor Agonist JAMA Neurology. ,vol. 30, pp. 383- 386 ,(1974) , 10.1001/ARCHNEUR.1974.00490350041006
A J Lees, K M Shaw, G M Stern, Baclofen in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. ,vol. 41, pp. 707- 708 ,(1978) , 10.1136/JNNP.41.8.707
M. Goldstein, A. Lieberman, J. Y. Lew, T. Asano, M. R. Rosenfeld, M. H. Makman, Interaction of pergolide with central dopaminergic receptors Proceedings of the National Academy of Sciences of the United States of America. ,vol. 77, pp. 3725- 3728 ,(1980) , 10.1073/PNAS.77.6.3725
I. SHOULSON, G. A. GLAUBIGER, T. N. CHASE, On‐off response Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients Neurology. ,vol. 25, pp. 1144- 1144 ,(1975) , 10.1212/WNL.25.12.1144
Reinhard Horowski, Hypothermic action of lisuride in rats and differences to bromocriptine in the antagonistic effect of neuroleptics. Naunyn-schmiedebergs Archives of Pharmacology. ,vol. 306, pp. 147- 151 ,(1979) , 10.1007/BF00498984
A.D. Ericsson, Potentiation of the l-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors Journal of the Neurological Sciences. ,vol. 14, pp. 193- 197 ,(1971) , 10.1016/0022-510X(71)90088-8
D. B. Calne, P. F. Teychenne, L. E. Claveria, R. Eastman, J. K. Greenacre, A. Petrie, Bromocriptine in Parkinsonism. BMJ. ,vol. 4, pp. 442- 444 ,(1974) , 10.1136/BMJ.4.5942.442
TYRONE LEE, P. SEEMAN, A. RAJPUT, IRENE J. FARLEY, O. HORNYKIEWICZ, Receptor basis for dopaminergic supersensitivity in Parkinson's disease Nature. ,vol. 273, pp. 59- 61 ,(1978) , 10.1038/273059A0